ADARx Pharmaceuticals, Inc. Chief Technology Officer Rui (NMN) Zhu received an award of employee stock options covering 512,076 shares of common stock on September 24, 2026. The options have a $17 per-share exercise price and expire September 23, 2036. One-quarter vests and becomes exercisable on September 24, 2027; the remainder vests and becomes exercisable in equal quarterly installments thereafter over three years, subject to Zhu's continued service on each vesting date.
ADARx Pharmaceuticals, Inc. Chief Scientific Officer Alan Robert MacLeod was granted employee stock options covering 170,692 common shares on September 24, 2026, at an exercise price of $17 per share. One-fourth of the shares vest and become exercisable on September 24, 2027; the remaining shares vest in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. reported that CFO and CBO Ryan Fisk received a direct grant of options covering 170,692 common shares on September 24, 2026, with a $17 exercise price. One-fourth of the shares vest and become exercisable on September 24, 2027; the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. President and CEO Zhen Li received an employee stock option award covering 1,024,152 common shares on September 24, 2026, with an exercise price of $17.00 per share. One-fourth vests and becomes exercisable on September 24, 2027; the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. Chief People Officer Robert William Ackles received an employee stock option award covering 85,346 shares, with an exercise price of $17.00 per share. One quarter vests and becomes exercisable on September 24, 2027; the remaining options vest in equal quarterly installments over three years, subject to his continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. closed its initial public offering on September 28, 2026, selling 26,250,000 shares of common stock at $17.00 per share. Gross IPO proceeds were approximately $446.3 million before underwriting discounts and commissions and estimated offering expenses payable by the company.
At the same closing, AbbVie Inc. purchased 5,255,542 shares in a private placement at the IPO price, generating approximately $89.3 million in gross proceeds before placement-agent fees and estimated private-placement expenses payable by ADARx. The purchase agreement set the share amount to result in AbbVie owning approximately 4.9% of common stock following the IPO and private placement, and capped its purchase at $100.0 million. ADARx paid a placement-agent fee equal to 2.0% of the total purchase price. The amended and restated certificate of incorporation and bylaws took effect in connection with the IPO closing; both had previously been approved by the board and stockholders. Ryan Fisk, the Chief Financial Officer and Chief Business Officer, signed the report.
ADARx Pharmaceuticals, Inc. (ADRX) is offering 26,250,000 shares of common stock in its IPO at $17.00 per share. The company lists proceeds of $415,012,500 before expenses. Underwriters may buy up to 3,937,500 additional shares during a 30-day option. Separately, AbbVie agreed to buy 5,233,264 shares in a concurrent private placement, contingent on the IPO closing; the purchase is capped at $100.0 million and would give AbbVie approximately 4.9% of post-closing shares.
ADARx develops siRNA medicines, with three clinical-stage and two advanced preclinical programs. For the six months ended June 30, 2026, collaboration revenue was $2.886 million, compared with $208,000 in 2025, while net loss was $48.426 million versus $33.644 million. Cash, cash equivalents and short-term investments totaled $427.252 million as of June 30, 2026. Based on current operating plans, ADARx says net proceeds from this offering and the private placement, together with existing cash, are expected to fund projected operating expenses and capital expenditure requirements into 2030.
ADARx Pharmaceuticals, Inc. reports director and 10% owner George Simeon’s indirect preferred-stock holdings through three SR One entities as of September 24, 2026. SR One Capital Fund I Aggregator, LP’s Series B and B-1 positions represent 3,334,938 and 1,113,666 common shares upon conversion; SR One Capital Opportunities Fund I, LP’s Series C position represents 512,897. SR One Co-Invest III, LLC’s Series B, B-1 and C positions represent 1,667,468, 169,001 and 1,538,691 common shares. The preferred stock automatically converts on a 1-for-1.1717 basis upon the IPO closing without further consideration; the share counts reflect conversion. Simeon disclaims beneficial ownership of portions in which he has no pecuniary interest.
SR One Capital Management, LLC, identified as a 10% owner of ADARx Pharmaceuticals, Inc. (ADRX), reported indirect preferred-stock positions held directly by three investment entities. SR One Capital Fund I Aggregator, LP holds Series B and Series B-1 positions corresponding to 3,334,938 and 1,113,666 Common Stock shares; SR One Capital Opportunities Fund I, LP holds a Series C position corresponding to 512,897 shares; SR One Co-Invest III, LLC holds Series B, Series B-1, and Series C positions corresponding to 1,667,468, 169,001, and 1,538,691 shares, respectively.
These counts give effect to automatic conversion at 1-for-1.1717 upon closing of ADARx’s initial public offering, without further consideration. Footnotes state that Simeon George, M.D., managing member of SR One Capital Management, and related general partners or managers may be deemed to share voting or disposition power and disclaim beneficial ownership except to the extent of any pecuniary interest.